Berberine - properties, dosage, and safety 2026

Berberine is described online as natural metformin, and this comparison does not hold up against the sources. The pilot study by Yin in 2008 indeed showed a decrease in glycosylated hemoglobin similar to that after metformin, but it involved 36 individuals in one center (Yin, Metabolism, 2008). This text clarifies what was actually measured, in which groups, and with what caveats from the authors. Separately, we point out the numbers that circulate under the names of Yin, Kong, Dong, and Lan, which do not appear in these studies because they were created by merging results from three different meta-analyses. You will also find what the studies did not verify: absorption in humans, safety longer than a few months, and the effects of combining with chronic medications. Each dose listed below describes the protocol of a specific study and is not a recommendation for the reader.

KEY INFORMATION
• In the Yin study, 36 individuals with newly diagnosed type 2 diabetes experienced a decrease in HbA1c from 9.5% to 7.5% over three months (Metabolism, 2008).
• The absolute oral bioavailability of berberine in rats was 0.36% (Liu, Drug Metabolism and Disposition, 2010).
• A meta-analysis of eleven studies reported a decrease in LDL cholesterol by 0.65 mmol/l (Dong, Planta Medica, 2013).
• Berberine displaces bilirubin from its binding with albumin, which is why it is not recommended for newborns with jaundice and for pregnant women (Chan, Biology of the Neonate, 1993).
• The Memorial Sloan Kettering Center notes a decrease in the activity of CYP2D6, CYP2C9, and CYP3A4 after repeated oral administration.

What is berberine and in which plants does it occur?

Berberine is an isoquinoline alkaloid with an intense yellow color, found in the bark, roots, and rhizomes of a few plant species. The Memorial Sloan Kettering monograph lists five species: common barberry (Berberis vulgaris), Coptis chinensis, Canadian goldenseal (Hydrastis canadensis), Berberis aristata, and Oregon grape, described there as Berberis aquifolium (Memorial Sloan Kettering, 2024).

The same monograph describes traditional uses without specifying the number of centuries. Berberine has been and is used in traditional Chinese medicine, Ayurveda, and other healing traditions for infections, diarrhea, and inflammatory disorders. The popular statement in supplement texts about two and a half thousand years of documented use does not originate from this source and was removed from the article along with the claim of thirty types of plants containing this alkaloid.

The distinction between the plant and the preparation is practically significant here. A decoction from the root and a standardized extract in a capsule are two different things in terms of the amount of active substance taken daily, and the clinical studies discussed below were conducted exclusively on preparations with a specified content. Transferring conclusions from these studies to any product off the shelf requires checking how much berberine the manufacturer declares and whether the declaration refers to pure alkaloid or the mass of the extract.

Why is berberine hardly absorbed?

Pharmacokinetics is the most interesting and often misrepresented part of the knowledge about this alkaloid. Liu and colleagues administered berberine to rats via four routes: gastric, duodenal, portal vein, and intravenous, to separate gastric, intestinal, and hepatic elimination. After gastric administration, approximately half of the dose passed through the digestive tract unchanged, while the other half was eliminated by the small intestine. The absolute oral bioavailability in rats was 0.36% (Liu, Drug Metabolism and Disposition, 2010).

The second observation from this study concerns where the substance accumulates. The area under the concentration curve in the liver was seventy times greater than that in plasma. The authors indicate intestinal elimination of the first pass as the main barrier to bioavailability, and high uptake and accumulation in the liver as the second reason for low concentrations in the blood. Three main metabolites were formed in the intestine, designated as M1, glucuronide M2, and M3. They were identified in multiple materials simultaneously: in the S9 fraction of rat enterocytes, in the plasma of the portal vein, and in the perfusion fluid of the intestine, allowing for the separation of the site of formation from the site of accumulation.

Two things must be stated clearly regarding this work. First, the measurement was performed in rats, so transferring the value of 0.36% to humans is an assumption, not a result. Second, the widespread range of 0.5-5% does not appear in this publication in any form and was removed from the article. Low bioavailability is sometimes presented today as an advantage because part of the dose acts locally in the intestine, but this interpretation is a hypothesis, not a conclusion of the cited work.

How does berberine work at the cellular level?

The best-documented mechanism was described by Turner and colleagues in 2008. Depending on the dose, berberine inhibited respiration in L6 muscle cells and in isolated muscle mitochondria, selectively acting on complex I of the respiratory chain, similar to metformin and rosiglitazone (Turner, Diabetes, 2008). Inhibition of respiration reduces the energy supply of the cell, which activates AMP-activated kinase, abbreviated as AMPK.

The way in which this kinase is activated turned out to be non-obvious. Activation of AMPK by berberine did not depend on the activity of LKB1 kinase or CAMKK beta kinase, which the authors explain by regulation at the level of the phosphatase that removes the phosphate group from AMPK itself. The same team described a derivative called dihydroberberine, which acted more effectively in the body, countering fat tissue growth, triglyceride accumulation in tissues, and insulin resistance in rodents fed a high-fat diet.

The authors attribute this advantage to presumably better absorption after oral administration, but the word presumably should not be overlooked, as they did not measure it directly. The circulating figures about five times better absorption of dihydroberberine and ten times better absorption of the phytosomal form do not come from this work and were removed along with the assigned doses. The study was conducted on rodents, not humans, and should be described as such.

Does berberine work the same way as metformin?

The statement about the identical mechanism of both substances is almost mandatory in supplement texts, yet it is based on weaker grounds than assumed. Turner indeed showed that both inhibit complex I of the respiratory chain. The problem is that the role of AMPK in the action of metformin itself was questioned during the same period.

Foretz and colleagues tested this in mice lacking AMPK in the liver. The blood glucose concentration in these animals did not differ from that in wild-type mice, and the glucose-lowering effect of metformin remained intact. Hepatocytes without AMPK produced glucose normally. Moreover, the inhibition of glucose production by metformin was even stronger in cells lacking AMPK and LKB1 than in control cells, and its magnitude correlated with a decrease in ATP content within the cell. The authors' conclusion is unequivocal: metformin inhibits hepatic glucose production independently of LKB1 and AMPK by lowering the energy state of the liver (Foretz, Journal of Clinical Investigation, 2010).

What does this imply for berberine? The common cause is the reduction of the energy supply of the cell after the inhibition of complex I. The messenger that is attributed to the subsequent signaling is disputed. Therefore, the statement about the identical mechanism should be replaced with a more cautious one: both substances hit the same point of the respiratory chain, while the further signaling pathway remains a matter of dispute. We will expand on the comparison of both substances in a separate text about berberynie i metforminie.

What exactly did the Yin study from 2008 show?

This study is the foundation of the entire popularity of berberine, so it is worth knowing its size. The authors describe it directly as a pilot study and divide it into two parts. In part A, thirty-six adults with newly diagnosed type 2 diabetes were randomly assigned to either berberine or metformin, both at a dose of 0.5 g three times a day, totaling 1.5 g per day, for three months. The glucose-lowering effect was similar in both groups (Yin, Metabolism, 2008).

In part B, forty-eight individuals with poorly controlled type 2 diabetes received berberine as an addition to their existing treatment. Glycated hemoglobin decreased from 8.1% to 7.3%, fasting insulin dropped by 28.1%, and the HOMA insulin resistance index decreased by 44.7%. Total cholesterol and LDL fraction also decreased. Twenty participants, or 34.5% of those studied, reported transient gastrointestinal discomfort, while no liver or kidney damage was found in anyone.

One number requires clarification. The percentage of 34.5% describes all transient gastrointestinal complaints in this study, not just diarrhea, and comes from the Yin work, not from the meta-analysis by Lan, to which it was attributed in the previous version of the article. It is also worth noting the speed of action in part B: the authors observed a decrease in fasting and postprandial glucose from the first week until the end of the study, not just after several months.

What do meta-analyses say about the effectiveness of berberine?

Meta-analyses are three, and confusing them with one another is the most common mistake in texts about berberine. They differ in the number of studies and the subject of evaluation.

The summary of 27 studies with 2569 patients comes from Lan, and the decrease in LDL by 0.65 mmol/l is from Dong z 2013 roku. The previous version of this article combined both values into one sentence and attributed them to Dong's work from the journal eCAM, which provides completely different numbers. The values for the decrease in glycosylated hemoglobin by 0.71 percentage points and fasting glucose by 0.69 mmol/l do not appear in the summary of any of the three studies and have been removed.

The authors' disclaimer is stronger than the results themselves. All three teams assessed the methodological quality of the included studies as generally low. Lan states directly that the therapeutic benefit of berberine can only be confirmed to a limited extent and that larger controlled studies are needed, conducted on a standardized preparation.

The comparison layout in Lan is also noteworthy. The analysis is divided into seven subgroups, and the outcome depends on what berberine was compared to. Compared to lifestyle modification alone or placebo, it performed better in terms of fasting glucose, postprandial glucose, and glycosylated hemoglobin. There was no statistically significant difference compared to oral antidiabetic medications. Compared to oral lipid-lowering medications, it did not differ in total cholesterol and LDL fractions, but it performed better in terms of triglycerides and HDL cholesterol. The statement about the superiority of berberine over medications is therefore true only for one of these subgroups.

How does berberine affect cholesterol?

Kong's work from 2004 remains the most frequently cited source on this topic and is the only one describing a mechanism different from that of statins. In thirty-two individuals with hypercholesterolemia, three months of oral administration reduced total cholesterol by 29%, triglycerides by 35%, and LDL cholesterol by 25% (Kong, Nature Medicine, 2004). In hamsters with hyperlipidemia, the decreases were greater: total cholesterol by 40%, LDL by 42%.

The authors traced the mechanism in human hepatocellular carcinoma cells. Berberine increases the amount of LDL receptor, but not through sterol regulatory element-binding proteins, but through an ERK kinase-dependent pathway. It acts after transcription is completed, stabilizing the mRNA of the receptor, and the segment responsible for this effect was located in the non-translated region at the 3' end. In the livers of hamsters, the amount of mRNA of the receptor increased three and a half times, and the amount of the receptor protein itself increased two and six-tenths times.

The summary of this work does not provide the dose used in humans, so the widespread record of administering 500 mg twice daily for three months has been removed from the article as unverified. It also does not contain a statement about confirming the mechanism in cells lacking HMG-CoA reductase activity. The difference in the pathway from that of statins is noted in this work, but the conclusion about combining both substances does not follow from it.

What does a decrease in HbA1c by one percentage point mean?

The mere change in laboratory results says little until it is compared with the risk of complications. The answer is provided by the observational analysis of the British UKPDS study, which included 4585 patients from twenty-three hospital centers (Stratton, BMJ, 2000). The authors calculated how much the risk decreases with a one percentage point reduction in average glycosylated hemoglobin.

The previous version of the article attributed a value of 21% to microvascular complications, which belongs to two other endpoints. The correct value is 37%, and this is also the largest of the four effects. The authors found no threshold below which the risk would stop decreasing, and the lowest risk was observed in individuals with glycosylated hemoglobin in the normal range. All four values are statistically significant, and the confidence interval for any diabetes-related endpoint ranged from 17% to 24%. A total of 3642 patients out of 4585 included in the incidence analysis were included in the relative risk analysis.

However, it should be noted that this is an observational analysis, not a randomized trial. It shows the relationship between glycemic control and complications, not the effectiveness of any specific preparation. Participants were patients treated in the British healthcare system, of European, South Asian, and Afro-Caribbean descent, and the observation was conducted over years. Transferring these proportions to a three-month supplement study is an extension that the authors do not propose. We have compiled other supplements studied in this regard in a ranking of supplements for insulin resistance.

Does berberine change gut microbiota?

Yes, and it is one of the best-documented topics, although not in humans. Zhang and colleagues administered berberine and metformin to rats with diet-induced obesity. Both substances shifted the overall structure of the microbiota in a similar direction and both reversed the changes caused by the diet alone. The diversity of the microbiota significantly decreased after both preparations (Zhang, Scientific Reports, 2015).

The analysis identified 134 taxonomic units responding to treatment. Sixty of them were reduced by both substances, while bacteria classified as short-chain fatty acid producers clearly increased. The mentioned genera are Allobaculum, Bacteroides, Blautia, Butyricoccus, and Phascolarctobacterium, with the effect being stronger after berberine than after metformin.

The names that appear in popular texts in this place do not appear in the cited work. There is neither Akkermansia muciniphila, nor an increase in this population by 100-300%, nor Faecalibacterium prausnitzii, nor a decrease in lipopolysaccharide-producing bacteria. All these claims have been removed from the article. Akkermansia itself was studied in humans, only administered directly, not stimulated by berberine: in a three-month placebo-controlled study in overweight individuals, the pasteurized version improved insulin sensitivity by 28.62% and reduced total cholesterol by 8.68% (Depommier, Nature Medicine, 2019). This is a separate intervention and should not be attributed to berberine. The study included forty individuals, and thirty-two completed it; ten billion bacteria were administered daily, either live or pasteurized, for three months. The procedure proved safe and well-tolerated, and insulin levels decreased by 34.08%.

Jakie dawki stosowano w badaniach klinicznych?

The table below is not a dosing scheme or recommendation. It summarizes the protocols of the studies described in this article so that the reader can see where the numbers repeated in product descriptions come from and discuss them with their doctor. The decision about any supplementation is made by the treating physician, not the article.

The article has omitted the entire scheme for introducing the preparation week by week, dividing the day into three doses with meals, twelve-week cycles with a four-week break, and the schedule for control examinations. None of these elements appear in the cited works, and all were presented as recommendations for the reader. The statement about a 70% reduction in gastrointestinal complaints with a gradual increase in dosage has also disappeared, as there is no source for it.

It is also worth noting what the studies did not cover. All three clinical studies discussed above lasted three months, and the meta-analyses collected studies of similar duration. There is no data on safety for use over a year or longer in these sources, so claims about long-term safety profiles cannot be substantiated in any way.

When is berberine contraindicated?

The most well-documented contraindication concerns newborns and pregnant women and is based on Chan's work from 1993. The author studied the effect of berberine on the binding of bilirubin to protein, starting from reports of the risk of kernicterus in Chinese infants with jaundice. In an in vitro study, berberine displaced bilirubin approximately ten times more effectively than phenylbutazone, considered a strong displacing agent, and about a hundred times more effectively than papaverine (Chan, Biology of the Neonate, 1993).

The experimental part also included animals. Intraperitoneal administration of berberine to adult rats daily for a week significantly reduced the average binding of bilirubin to serum proteins and maintained elevated levels of free and total bilirubin, likely also by inhibiting its metabolism. The author's conclusion is that herbs with high berberine content should be avoided in newborns with jaundice and in pregnant women.

The Memorial Sloan Kettering monograph formulates the same warning in clinical language: berberine may exacerbate jaundice in infants or lead to kernicterus, a condition where prolonged high levels of bilirubin cause irreversible consequences. The center advises against use during pregnancy and breastfeeding. The mild side effects described there include loss of appetite, gastrointestinal discomfort, diarrhea, constipation, and rash, with generally good tolerance of the preparation.

What distinguishes a supplement from a drug here?

This difference is not a formality and stems directly from the authors' own reservations in the meta-analyses. Lan and colleagues conclude their work with the statement that berberine has a comparable therapeutic effect in type 2 diabetes, hyperlipidemia, and hypertension, and no serious adverse effects have been reported, but they then add two sentences that are usually omitted in reprints. Due to the generally limited quality of the included studies, the therapeutic benefit can only be confirmed to a limited extent, and larger controlled studies conducted on a standardized preparation are needed for its quantitative assessment (Lan, Journal of Ethnopharmacology, 2015).

The term standardized is the focal point here. A clinical study is conducted on a preparation with known and repeatable active substance content, whereas a dietary supplement is not subject to pharmacopoeial standards that would guarantee such repeatability in every capsule. Therefore, the result obtained on one preparation does not automatically transfer to another product with the same common name.

The second reservation concerns the origin of the data. Dong and colleagues assess the methodological quality of the included studies as generally low and point to small group sizes, a limited number of studies, and unrecognized risk of systematic error as reasons why conclusions should be read cautiously (Dong, eCAM, 2012). This is not an argument against berberine, but an indication of the level of evidence on which the discussion about it currently stands.

Jakie interakcje lekowe opisano dla berberyny?

Interactions are the part of the topic where popular articles diverge most from the source, usually by providing precise percentages without backing. The Memorial Sloan Kettering monograph notes that repeated oral administration of berberine significantly reduced the activity of isoenzymes CYP2D6, CYP2C9, and CYP3A4, and warns against combining it with drugs that are substrates of these enzymes. It separately mentions the increase in blood levels of cyclosporine in adults after kidney transplantation.

There are four things missing in this source, and all were removed from the article. There is no number describing the increase in cyclosporine levels by 24-29%. There is no mention of P-glycoprotein or the blood-brain barrier. There is also no claim that cytochrome CYP3A4 processes half of the drugs on the market, nor named interactions with statins, warfarin, and metformin, even though all four sentences previously stood under the same reference.

Caution remains derived directly from what has been measured. Since berberine lowers the activity of three isoenzymes responsible for the metabolism of many drugs, any combination with chronic pharmacotherapy requires evaluation by a doctor or pharmacist. Since in the Yin study it lowered blood glucose to a degree comparable to metformin, adding it to diabetes treatment sums two actions in the same direction, rather than being a neutral addition. A similar warning applies to other substances affecting blood glucose, as we mentioned in apple cider vinegar and glycemia.

What should I ask my doctor before reaching for berberine?

Talking to a doctor is a condition here, not a formality, and it is best to enter it prepared. Bring a complete list of medications you are taking, including supplements and herbs, as most of the doubts described in the previous section are resolved on this list. Include current results that the doctor will order anyway: fasting blood glucose, hemoglobin A1c, lipid profile, and liver function tests.

Also name the goal. The conversation about support for prediabetes looks different than one about lipid disorders, and even more so about adding a preparation to diagnosed type 2 diabetes treated pharmacologically. The latter situation is the most difficult for the reasons described and requires a discussion with a diabetologist, rather than a decision made independently at the shelf.

Three questions are worth asking directly. Is this substance safe in my situation? Does any of my medications go through the isoenzymes whose activity it lowers? What parameters and how often should we monitor if we decide to try it? If you are taking medications after an organ transplant, are pregnant, breastfeeding, or planning a surgical procedure, the starting point is rather to refrain than to establish a method of administration.

There is one more question worth asking yourself before the visit: how will I know if it works? In the studies described above, the reference points were hemoglobin A1c, fasting blood glucose, and postprandial glucose, measured at intervals of several months. Well-being or body weight were not measures of effectiveness in these works, so evaluating the preparation after a week of observation has no basis in any of the cited studies.

Frequently Asked Questions

What is berberine and where does it come from?

It is an isoquinoline alkaloid with a yellow color. The Memorial Sloan Kettering monograph lists five species in which it occurs: Berberis vulgaris, Coptis chinensis, Hydrastis canadensis, Berberis aristata, and Berberis aquifolium. It is used in traditional Chinese medicine and Ayurveda for infections, diarrhea, and inflammatory disorders (Memorial Sloan Kettering, 2024).

How much did berberine lower glycosylated hemoglobin?

In a pilot study by Yin, thirty-six individuals with newly diagnosed type 2 diabetes took 0.5 g three times daily for three months. Glycosylated hemoglobin decreased in this group from 9.5% to 7.5%, and the glucose-lowering effect was similar to that of metformin at the same dose (Metabolism, 2008).

Does berberine act through the same mechanism as metformin?

Both inhibit complex I of the respiratory chain (Turner, Diabetes, 2008). The continuation is disputed: in mice lacking AMPK in the liver, the glucose-lowering effect of metformin remained preserved, so the authors attributed it to a decrease in the liver's energy status rather than to this kinase (Foretz, Journal of Clinical Investigation, 2010).

How does berberine affect cholesterol?

In thirty-two individuals with hypercholesterolemia, three months of oral administration reduced total cholesterol by 29%, triglycerides by 35%, and LDL fraction by 25%. The mechanism involves stabilizing the informational RNA of the LDL receptor and is different from the mechanism of statins (Kong, Nature Medicine, 2004).

Is berberine absorbed from the gastrointestinal tract?

Very poorly. In rats, the absolute oral bioavailability was 0.36%, with about half of the dose passing through the gastrointestinal tract unchanged, and the substance primarily accumulated in the liver (Liu, Drug Metabolism and Disposition, 2010). This measurement has not been performed in humans.

Is berberine safe during pregnancy and for newborns?

No. Berberine displaces bilirubin from its binding with albumin much more effectively than phenylbutazone, and the author of the study advises against herbs with high content in newborns with jaundice and in pregnant women (Chan, Biology of the Neonate, 1993). Memorial Sloan Kettering also advises against use during breastfeeding.

Jakie interakcje lekowe opisano dla berberyny?

Repeated oral administration significantly reduced the activity of three cytochrome isoenzymes: CYP2D6, CYP2C9, and CYP3A4. In adults after kidney transplantation, berberine increased the concentration of cyclosporine in the blood (Memorial Sloan Kettering, 2024). Combining it with any chronically taken medication requires prior assessment by a doctor or pharmacist, not a decision made independently.

Does berberine change gut microbiota?

In rats on a high-fat diet, berberine and metformin shifted the microbiota structure in a similar direction, reduced its diversity, and increased bacteria producing short-chain fatty acids, including the genera Allobaculum and Butyricoccus (Zhang, Scientific Reports, 2015). The effect was stronger after berberine than after metformin. This has not been tested in humans.

Summary

Berberine has a real, repeatedly measured effect on blood glucose and lipid profile, while having a significantly narrower evidence base than would be suggested by product descriptions. Three meta-analyses consistently assess the methodological quality of the included studies as low, and the largest of them found no statistically significant difference between berberine and oral antidiabetic medications. The study that built its popularity is directly called pilot and included thirty-six individuals in one center.

Comparing it to metformin should be done more cautiously than most texts do. They share a site of action in the respiratory chain, the messenger responsible for the further process is disputed, and above all, the status of both substances is different: one is a drug with decades of safety data, the other is a supplement without pharmacopoeial standards and without guarantees of repeatable content in the capsule.

From this edition, we have removed seven incorrect identifiers, each leading to work from a different field, the entire dosing scheme provided as a recommendation, and all numbers that are not found in the cited sources, including statistics described as the store's own observations. Absolute contraindications remain in effect: pregnancy, breastfeeding, and the neonatal period.

This article is for informational and educational purposes and does not constitute medical advice. Before starting supplementation, consult your doctor, especially if you are taking medications regularly, are pregnant or breastfeeding, or have a chronic illness.

Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-10